eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion

Rhea-AI Summary

eXoZymes (NASDAQ:EXOZ) reported a successful 100× scale-up of its N-trans-caffeoyltyramine (NCT) production using its cell-free, exozyme-based biomanufacturing platform on December 11, 2025. The scaled run delivered >99% conversion from feedstock to product and was executed under partner-operated conditions by Cayman Chemical, demonstrating process transferability and robustness. eXoZymes said downstream isolation and full data analysis are ongoing, with additional technical details expected in early 2026.

Positive

• Scale-up achieved: 100× increase in reaction volume
• Feedstock conversion: >99% at scale
• Partner validation: batch executed by Cayman Chemical
• Process attributes: demonstrated transferability and robustness

Negative

• Downstream isolation and NCT extraction still incomplete
• Full experimental data and technical details delayed until early 2026

News Market Reaction

-0.69%

1 alert

-0.69% News Effect

-$837K Valuation Impact

$120M Market Cap

1.2x Rel. Volume

On the day this news was published, EXOZ declined 0.69%, reflecting a mild negative market reaction. This price movement removed approximately $837K from the company's valuation, bringing the market cap to $120M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

NCT scale-up: 100-fold Feedstock conversion: over 99% Net loss (Q3 2025): $2,286,991 +5 more

8 metrics

NCT scale-up 100-fold Scale-up of NCT production using exozyme-based cell-free platform

Feedstock conversion over 99% Conversion from feedstock to NCT at large-scale batch conditions

Net loss (Q3 2025) $2,286,991 Quarter ended September 30, 2025 per 10-Q

Net loss (9M 2025) $6,503,698 Nine months ended September 30, 2025 per 10-Q

Cash and equivalents $5,098,687 Balance as of September 30, 2025

Operating cash outflows $4,528,240 Nine months ended September 30, 2025

Shares outstanding 8,387,250 As of November 13, 2025 per 10-Q

Days to cover 10.46 days Based on reported short-interest metric

Market Reality Check

Price: $10.51 Vol: Volume 12,442 is 4.97× th...

high vol

$10.51 Last Close

Volume Volume 12,442 is 4.97× the 20-day average of 2,504, indicating elevated interest ahead of this milestone. high

Technical Trading above 200-day MA at 12.86, 33.26% below 52-week high of 23.99 and 80.7% above 52-week low of 8.86.

Peers on Argus

EXOZ gained 14.28% while close peers were mixed, with ADAG down 7.65%, ARMP down...

EXOZ gained 14.28% while close peers were mixed, with ADAG down 7.65%, ARMP down 4.71%, and others like TCRX and FATE up low single digits, pointing to a stock-specific reaction.

Historical Context

5 past events · Latest: Nov 13 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 13	Q3 update webinar	Neutral	-0.6%	Quarterly update webinar and operational review for Q3 2025.
Nov 13	Leadership changes	Neutral	-0.6%	Appointment of co-founder as CSO and naming of new chief of staff.
Nov 10	Earnings call notice	Neutral	+14.3%	Announcement of upcoming Third Quarter 2025 investor webinar.
Oct 30	AI panel participation	Neutral	+13.9%	CEO participation on AI in life sciences panel spotlighting exozymes platform.
Oct 29	Investor conference talk	Neutral	+13.9%	CEO presentation at investor conference on AI-engineered biomanufacturing and NCT.

Pattern Detected

Shares have previously shown strong positive moves on visibility and platform-focused news, including conference appearances and update announcements.

Recent Company History

Over the last few months, eXoZymes has focused on investor communication and platform positioning. In late October and early November, CEO presentations and an AI-in-life-sciences panel highlighted its cell-free biomanufacturing platform and flagship NCT molecule, with shares rising double digits after some of these events. On November 13, 2025, Q3 updates and leadership changes coincided with modest declines. Today’s news adds concrete technical validation, showing a 100× NCT scale-up and >99% conversion, advancing the same NCT-centric story.

Market Pulse Summary

This announcement detailed a major technical milestone: a 100× scale-up of NCT production with over ...

Analysis

This announcement detailed a major technical milestone: a 100× scale-up of NCT production with over 99% feedstock conversion on the exozyme-based, cell-free platform. It builds on earlier communications positioning NCT as a flagship molecule. At the same time, the latest 10-Q showed a quarterly net loss of $2.29M, nine‑month loss of $6.50M, and going concern language, so investors may watch future data releases and financing steps closely.

Key Terms

cell-free biomanufacturing, biocatalytic, downstream analysis, going concern

4 terms

cell-free biomanufacturing technical

"exozyme-based, cell-free biomanufacturing platform."

Cell-free biomanufacturing makes biological products — like proteins, enzymes or vaccine ingredients — by using the molecular machinery of cells removed from living organisms, rather than growing whole cells. Investors should care because this approach can speed up production, cut costs and reduce contamination risk, making supply chains more flexible and potentially changing how quickly and cheaply biotech products reach the market.

biocatalytic technical

""Scaling a complex biocatalytic reaction by 100× while sustaining high feedstock"

Biocatalytic describes processes that use biological molecules or whole cells—most often enzymes—to speed and guide chemical reactions, acting like nature’s specialized tools for building or modifying molecules. For investors, biocatalytic methods can cut manufacturing costs, reduce waste and regulatory risk, and enable novel or harder-to-make products, so firms that successfully apply them may gain cleaner, faster and more cost‑effective production compared with traditional chemistry.

downstream analysis technical

"following completion of downstream analysis and NCT extraction."

Downstream analysis is the set of follow-up examinations performed after initial data or results are produced, used to interpret what those results actually mean for performance, safety or value. For investors, it reveals hidden patterns, risks or opportunities that aren’t obvious from headline results—like checking the fine print after a score is announced—to judge whether a development will affect revenue, regulatory approval, costs or future growth.

going concern financial

"reporting continued operating losses and a going concern warning."

A going concern is a business that is expected to continue its operations and meet its obligations for the foreseeable future, rather than shutting down or selling off assets. This assumption matters to investors because it indicates stability and ongoing profitability, making the business a more reliable investment. Think of it as believing a restaurant will stay open and serve customers, rather than closing down suddenly.

AI-generated analysis. Not financial advice.

LOS ANGELES, CALIFORNIA / ACCESS Newswire / December 11, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - announced the successful achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process using its proprietary exozyme-based, cell-free biomanufacturing platform. This effort, with a conversion level of over 99% from feedstock to product, marks a major milestone in the scalability of the exozymes platform.

"Scaling a complex biocatalytic reaction by 100× while sustaining high feedstock conversion strengthens our belief that exozymes will form the foundation of the next generation of biomanufacturing," said Michael Heltzen, CEO of eXoZymes. "We're very enthusiastic about this progress and see it as an important inflection point in demonstrating that cell-free, enzyme-driven systems can be engineered to operate reliably at scale. This truly opens the door to producing molecules that have historically been constrained by traditional manufacturing approaches."

The scaled reaction maintained exceptionally high conversion efficiency, demonstrating near-complete transformation of input feedstock into target product under large-volume operating conditions. This performance confirms that the exozyme-driven process not only scales linearly but can match - or exceed - conversion levels observed at smaller scales. The batch production was executed using standardized protocols under partner-operated conditions by Cayman Chemical, underscoring the robustness, transferability, and scalability of the process and technology.

Dr. Tyler Korman, CSO of eXoZymes, adds, "Scaling while preserving reaction performance has historically been challenging, and this outcome supports the growing body of evidence that cell-free enzyme production pathways - aka exozymes systems - can overcome fundamental limitations associated with traditional biomanufacturing approaches. Achieving over 99% conversion at scale is a significant validation of our exozyme biosolution - both from a scientific as well as a commercial point of view."

Cayman Chemical and eXoZymes are working on the isolation process for NCT as well as still analyzing the data from the experiment. Additional technical details are expected to be published in a subsequent press release following completion of downstream analysis and NCT extraction. Due to the magnitude of the work and the upcoming holidays, this additional information should not be expected until early 2026.

About Cayman

Cayman Chemical helps make research possible by providing products and services to scientists worldwide. Cayman's collection includes high-quality biochemicals, assay kits, antibodies, and proteins, empowering researchers to understand the biological mechanisms of health and disease and develop new therapies. Cayman's scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, and fatty acids, and is highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination. In addition, Cayman offers a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques. Cayman performs generic drug development and production in both Ann Arbor, Michigan and Neratovice, Czech Republic.

Learn more at www.caymanchem.com

About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce very valuable natural products, via a commercially scalable, sustainable, and eco-friendly alternative: exozymes.

Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, nutraceuticals and medicines.

By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.

While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.

Learn more at exozymes.com

eXoZymes Safe Harbor

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.

eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com

https://www.linkedin.com/company/exozymes
https://x.com/exozymes
https://www.youtube.com/@exozymes

SOURCE: eXoZymes

View the original press release on ACCESS Newswire

FAQ

What did eXoZymes (EXOZ) announce about NCT production on December 11, 2025?

eXoZymes announced a 100× scale-up of NCT production with >99% feedstock conversion using its exozyme, cell-free platform.

How efficient was the scaled NCT run reported by EXOZ?

The company reported a conversion level of over 99% from feedstock to product at the scaled volume.

Who performed the partner-operated batch for EXOZ's scale-up and why does it matter?

The batch was executed by Cayman Chemical, which the company cites as evidence of process transferability and robustness.

Will eXoZymes publish the full NCT data and when can investors expect it?

eXoZymes said downstream analysis and isolation are ongoing and additional technical details are expected in early 2026.

Does the EXOZ announcement confirm commercial NCT production is underway?

No; the announcement reports a successful scaled experiment but notes that isolation and full data review are still in progress.